Here are three things to know:
1. The Mobi-C Cervical Disc is a motion-sparing technology designed to replace diseased discs and provide an alternative to fusion.
2. Mobi-C received FDA approval in 2013, becoming the first cervical disc to be approved at one- and two-levels. Five-year FDA clinical trial results found two-level cervical disc replacement patients who received Mobi-C experienced lower rates of revision surgeries and returned to activity three weeks earlier than fusion patients.
3. Dr. Waguespack is an orthopedic spine surgeon who received her medical degree from Louisiana State University School of Medicine in New Orleans. She underwent spine fellowship training at the San Francisco Spine Institute.
“For the first time, I am able to offer to many of my patients who suffer from two-level cervical disease a superior treatment option to traditional cervical spine fusion that maintains motion,” said Dr. Waguespack in a statement.
More articles on devices and implants:
Zimmer Biomet changes spine strategy, aims to launch robotic total knee by year end
SeaSpine reports $36.4M revenue in Q2, up 6.5%: 5 things to know
4 things to know about Johnson & Johnson’s $227M DoD spinal implant supply contract
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
